<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022230</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068797</org_study_id>
    <secondary_id>RWMC-0633846</secondary_id>
    <nct_id>NCT00022230</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer</brief_title>
  <official_title>Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roger Williams Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roger Williams Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Biological therapies use different ways to stimulate the immune&#xD;
      system and stop tumor cells from growing. Combining chemotherapy with biological therapy may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of giving chemotherapy together&#xD;
      with biological therapy and to see how well they work in treating patients with stage II or&#xD;
      stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxic effects of sequential paclitaxel (or other taxane), doxorubicin, and&#xD;
           cyclophosphamide followed by immunotherapy with activated T cells, interleukin-2, and&#xD;
           sargramostim (GM-CSF) in patients with high-risk stage II or III breast cancer.&#xD;
&#xD;
        -  Determine the disease-free survival and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the immune function of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to number of positive lymph nodes (less than 4&#xD;
      nodes vs 4-9 nodes vs 10 or more nodes), type of taxane chemotherapy during study (paclitaxel&#xD;
      vs other taxane), and prior treatment with 2 of 3 study chemotherapy agents (yes vs no).&#xD;
&#xD;
      Patients receive doxorubicin IV on day 1 and filgrastim (G-CSF) on days 3-10 of 3 consecutive&#xD;
      14-day courses. Patients then receive paclitaxel or another taxane IV on day 1 and G-CSF on&#xD;
      days 3-10 of 3 consecutive 14-day courses. Patients then receive cyclophosphamide IV on day 1&#xD;
      and G-CSF on days 3-10 of 3 consecutive 14-day courses. Patients who enroll after previously&#xD;
      receiving 2 of these 3 chemotherapy drugs may receive the third. Treatment continues in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After recovery from chemotherapy, patients undergo peripheral blood mononuclear cell (PBMC)&#xD;
      collection. The PBMC are treated ex vivo with monoclonal antibody OKT3 to form activated T&#xD;
      cells (ATC). The ATC are expanded for up to 14 days in interleukin-2 (IL-2).&#xD;
&#xD;
      At 3-4 weeks after PBMC collection, patients receive ATC IV over 15-30 minutes weekly for 8&#xD;
      weeks. Patients also receive IL-2 subcutaneously (SC) daily and sargramostim (GM-CSF) SC&#xD;
      twice weekly beginning 3 days before the first ATC infusion and continuing until 7 days after&#xD;
      completion of ATC therapy.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40-60 patients will be accrued for this study within 4-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left Institution&#xD;
  </why_stopped>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune functions</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage II or III adenocarcinoma of the breast&#xD;
&#xD;
          -  High-risk disease&#xD;
&#xD;
               -  At least 4 positive lymph nodes&#xD;
&#xD;
               -  Fewer than 4 positive lymph nodes considered high-risk if one of the following is&#xD;
                  present:&#xD;
&#xD;
                    -  HER2/neu-positive disease&#xD;
&#xD;
                    -  Enlarged axillary nodes&#xD;
&#xD;
                    -  Extra capsular extension of tumor from lymph node&#xD;
&#xD;
                    -  Dermal lymphatic invasion&#xD;
&#xD;
                    -  Vascular invasion&#xD;
&#xD;
                    -  Bilateral disease&#xD;
&#xD;
                    -  Familial breast cancer&#xD;
&#xD;
                    -  T4 locally advanced disease&#xD;
&#xD;
          -  Clinically chemosensitive to prior paclitaxel (or other taxane), doxorubicin, and&#xD;
             cyclophosphamide&#xD;
&#xD;
               -  No relapse after chemotherapy&#xD;
&#xD;
          -  No clinical evidence of brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen and progesterone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100% OR&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times normal&#xD;
&#xD;
          -  SGOT less than 1.5 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.8 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  BUN less than 1.5 times normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 45% by MUGA&#xD;
&#xD;
          -  No uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No significant congestive heart failure&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1 at least 60% predicted&#xD;
&#xD;
          -  DLCO at least 60% predicted&#xD;
&#xD;
          -  FVC at least 60% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy except curatively treated squamous cell carcinoma in situ of the&#xD;
             cervix or basal cell skin cancer&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior standard chemotherapy with anthracyclines or combination chemotherapy involving&#xD;
             a combination of taxanes, doxorubicin, and/or cyclophosphamide allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy for breast cancer&#xD;
&#xD;
          -  Concurrent hormonal therapy for nondisease-related conditions (e.g., insulin for&#xD;
             diabetes) allowed&#xD;
&#xD;
          -  Concurrent steroids for adrenal failure, septic shock, or pulmonary toxicity allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior complete resection of tumor allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Prior successful neoadjuvant therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence G. Lum, MD, DSc</last_name>
    <role>Study Chair</role>
    <affiliation>Roger Williams Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roger Williams Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908-4735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <name_title>Lawrence Lum</name_title>
    <organization>Roger Williams Medical Center</organization>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

